|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:cyclosporine
|
|
gptkbp:approves
|
gptkb:1995
gptkb:FDA
|
|
gptkbp:associated_with
|
rheumatology
dermatology
gastroenterology
transplant medicine
|
|
gptkbp:brand
|
gptkb:Neoral
|
|
gptkbp:class
|
calcineurin inhibitors
|
|
gptkbp:clinical_trial
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
autoimmune diseases
psoriasis
|
|
gptkbp:contraindication
|
active infections
malignancies
hypersensitivity to cyclosporine
|
|
gptkbp:dosage_form
|
gptkb:beer
oral solution
|
|
gptkbp:education
|
take with food
regular follow-up appointments
report signs of infection
avoid grapefruit juice
|
|
gptkbp:formulation
|
oral solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Neoral
|
|
gptkbp:ingredients
|
gptkb:cyclosporine
|
|
gptkbp:interacts_with
|
antibiotics
antifungals
other immunosuppressants
NSAI Ds
|
|
gptkbp:invention
|
gptkb:2023
patented
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_monitored_by
|
blood pressure
kidney function
liver function
drug levels
|
|
gptkbp:is_used_for
|
preventing organ rejection
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:previous_name
|
gptkb:cyclosporine
|
|
gptkbp:side_effect
|
high blood pressure
kidney damage
increased risk of infections
tremors
liver dysfunction
|